Intellia Therapeutics, Inc.

Intellia Therapeutics is a biotechnology company focused on developing potentially curative genome editing treatments for severe diseases. They employ a full-spectrum approach, utilizing CRISPR technology for both in vivo and ex vivo therapies. The company's mission is to transform the lives of people with debilitating diseases by harnessing the power of CRISPR to create lasting, impactful changes to the genome.

Intellia has a strong pipeline of both wholly-owned and partnered programs. They are currently conducting a Phase 1 clinical trial for NTLA-2001 (nexiguran ziclumeran), a treatment for transthyretin (ATTR) amyloidosis. Other programs in their pipeline target hereditary angioedema (HAE), alpha-1 antitrypsin deficiency (AATD)-associated lung disease, hemophilia A and B, and other undisclosed indications. Intellia is committed to advancing their CRISPR technology to create a new era in medicine, offering hope for patients with currently untreatable conditions.

Intellia Therapeutics is a biotechnology company committed to revolutionizing medicine by developing potentially curative genome editing treatments. Their mission is to transform the lives of people with severe diseases by harnessing CRISPR-based gene editing technologies to address the root causes of genetic, oncological, and immunological disorders. Intellia is actively developing both in vivo and ex vivo therapies, striving to make CRISPR-based medicines a reality for patients suffering from genetic diseases and to create novel engineered cell therapies for various cancers and autoimmune diseases.

Intellia Therapeutics emphasizes a culture of diversity, equity, and inclusion. They celebrate and support individuals, working together as ONE, recognizing and valuing differences in race, gender, age, experience, and other unique characteristics. Their commitment to cultivating an equitable and inclusive environment is reflected in their support of various employee resource groups (ERGs) and external organizations focused on STEM outreach and diversity in the biotech industry.

Intellia Therapeutics is committed to building a diverse and inclusive workplace that reflects the diverse patient populations they serve. They believe that diversity is essential to achieving their mission of transforming lives with potentially curative genome editing treatments. To that end, they support various programs and initiatives, including employee resource groups (ERGs) that foster a sense of belonging and create opportunities for professional development. Intellia also sponsors organizations like UNCF and SACNAS, which promote educational opportunities and diversity in STEM fields.